Option chain shows key data for Protagonist Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) Stock, Option Chain

Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Johnson & Johnson Inc. JNJ

Biotech

Large Cap

News

Health Care

General

PTGX

Protagonist and Johnson &amp; Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Johnson &amp; Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

D-Wave Quantum Inc.

Equities

Mid Cap

Movers

Trading Ideas

HSAI

IONQ

ORLA

QBTS

RGTI

SMTC

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

GileadSciences.Shutterstock

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ASAN

AVPT

DRIO

GILD

OKUR

ORCL

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

Press Releases

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

TYO:4502

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Immunovant

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

Wedbush

Truist Securities

BMO Capital

Citizens Capital Markets

Comments

Protagonist Therapeutics

Protagonist Therapeutics (PTGX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell